Incyte Corporation (NASDAQ:INCY): $0.63 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 2.47. The value of trades done on upticks was $1.07 million, whereas, trades done on downticks were valued at $0.43 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.01 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.01 million. Incyte Corporation (NASDAQ:INCY) fell $0.74 traded at $75.84, a change of -0.97% over the previous day. The stock is -1.48% for the week.
In an insider trading activity,The officer (EVP, Human Resources) of Incyte Corp, Swain Paula J sold 13,531 shares at $76.96 on January 15, 2016. The Insider selling transaction had a total value worth of $1,041,346. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 13.7% of Incyte Corporation shares according to the proxy statements. Institutional Investors own 95.84% of Incyte Corporation shares.
The company shares have dropped -26.68% from its 1 Year high price. On Sep 16, 2015, the shares registered one year high at $133.62 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $79.32 and the 200 Day Moving Average price is recorded at $79.45. Incyte Corporation (NASDAQ:INCY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $77.15 and $75.82 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $79.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $78.74, notching a gain of 2.81% for the day. The total traded volume was 1,247,767 . The stock had closed at $76.58 on the previous day.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f